^
    over3years
    Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma. (PubMed, Front Oncol)
    Future Ad-p53 clinical trials should have favorable p53 biomarker profiles inclusion criteria and Ad-p53 dosing above 7 × 10 viral particles/cm of injected tumor volume. Preliminary gene expression profiling identified p53 mechanisms of action associated with responses to immune checkpoint blockade supporting evaluation of Ad-p53 in combination with immune checkpoint inhibitors.
    Clinical • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    TP53 mutation • TP53 deletion • TP53 expression
    |
    Ad-p53 gene therapy